MedTrace Logo

Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer

NCT06235853 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2024-02-01

No results posted yet for this study

Summary

Bladder cancer (BC) is one of the most common type of cancer globally. Due to its high incidence rate, high risk of recurrence and progression, and frequent cystoscopy surveillance, BC contributes to major healthcare costs across the world. The goal of this prospective study was to evaluate the prognostic value of novel non-muscle invasive bladder cancer (NMIBC) biomarkers for predicting disease recurrence or progression after radical transurethral resection of bladder tumour (TURBT). The data obtained from this study may help physicians identify patients who are at greater risk of NMIBC recurrence or progression and require close supervision.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood serum: sUPAR, PAI-1, IL-8.

The concentration of described biomarkers were measured in serum.

DIAGNOSTIC_TEST

Urine: IL-8, APOE, VEGF.

The concentration of described biomarkers were measured in urine.

Sponsors & Collaborators

  • Wroclaw Medical University

    lead OTHER

Principal Investigators

  • Klaudia Bardowska, MD · Wroclaw Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-12-31
Completion
2023-04-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06235853 on ClinicalTrials.gov